Volume | 280,114 |
|
|||||
News | - | ||||||
Day High | 3.64 | Low High |
|||||
Day Low | 3.16 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
NRX Pharmaceuticals Inc | NRXP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.26 | 3.16 | 3.64 | 3.54 | 3.14 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,704 | 280,114 | $ 3.42 | $ 959,031 | - | 2.21 - 12.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:56:20 | 91 | $ 3.80 | USD |
NRX Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
295.4M | 83.92M | - | 0 | -30.16M | -0.36 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
NRX Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NRXP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.07 | 3.64 | 2.7201 | 3.05 | 149,843 | 0.68 | 22.15% |
1 Month | 4.70 | 6.00 | 2.7201 | 4.64 | 342,856 | -0.95 | -20.21% |
3 Months | 3.85 | 7.333 | 2.7201 | 5.11 | 1,502,463 | -0.10 | -2.60% |
6 Months | 2.795 | 7.333 | 2.70 | 4.70 | 1,142,451 | 0.955 | 34.17% |
1 Year | 6.10 | 12.00 | 2.21 | 4.20 | 1,020,244 | -2.35 | -38.52% |
3 Years | 230.10 | 262.40 | 2.21 | 69.34 | 1,604,843 | -226.35 | -98.37% |
5 Years | 230.10 | 262.40 | 2.21 | 69.34 | 1,604,843 | -226.35 | -98.37% |
NRX Pharmaceuticals Description
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour. |